Open AccessPalbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR +/ HER2 – Advanced Breast Cancer
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13864
Subject(s) - fulvestrant , palbociclib , medicine , oncology , breast cancer , overall survival , cancer , metastatic breast cancer , gynecology , tamoxifen
With more than 6 years of follow‐up in the phase III PALOMA‐3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR‐positive, HER2‐negative advanced breast cancer that progressed on prior endocrine therapy.